Location: Home > Pharma China Web Edition
  • search
  • go
  • News
  • 7/9/2025Adagene and ConjugateBio Launch a Strategic Partnership to Advance Bis...
  • 7/8/2025ArkBio's ADHD Drug Azstarys Granted Priority Review in China
  • 7/8/2025U.S. Lawmakers Raise Fresh Alarm Over GenScript's China Links
  • 7/8/2025Novo Nordisk Commits CNY 800M to Expand Quality Lab at Tianjin Manufac...
  • 7/8/2025NMPA Releases 93rd Batch of Reference Formulations for Generic Drug Ev...
  • 7/8/2025China's NMPA Reopens Public Consultation on Revised Conditional Approv...
  • 7/8/2025XellSmart Completes New Financing, Secures FDA Clearance for iPSC-Deri...
  • 7/8/2025DualityBio Launches Phase 3 Trial of HER2 ADC DB‑1303 in China for Re...
  • 7/8/2025Hansoh Launches Phase 1 Combo Trial of HS‑20093 ADC in ES‑SCLC
  • 7/8/2025Fosun USA and MAP International Partner to Expand Medicine Access
  • 7/8/2025China Hospitals Prioritize Local Innovation, Digital Health, and Profi...
  • 7/8/2025CStone and Istituto Gentili Forge Partnership for Sugemalimab in Weste...
  • 7/8/2025SCG Cell's IND for SCG101V Cleared in China
  • 7/8/2025Sagent and Qilu Announce Partnership for Critical Injectables in U.S.
  • 7/8/2025China's Biotech Financing Hits 10-Year Low in First Half of 2025
  • 7/8/2025CStone Launches Global Phase I/II Trial for Trispecific Antibody CS200...
  • 7/8/2025China Approves 62 Novel Drugs in H1 2025, Led by Small Molecules and A...
  • 7/4/2025CDE Solicits Comments on the 95th Batch of Reference Formulations for ...
  • 7/4/2025CDE Seeks Comment on Revised eCTD Technical Documents and Mapping Tabl...
  • 7/4/2025AstraZeneca Eyes $15B Deal for Summit's Chinese-Developed Lung Cancer ...
  • 7/4/2025Legend Initiates First-in-Human Trial for LUCAR-G19 in Autoimmune Dise...
  • 7/4/2025Brii Biosciences Taps Joincare Pharma to Drive BRII‑693 in Greater Ch...
  • 7/4/2025Shaanxi Micot Secures 100M CNY in Series D Financing
  • 7/3/2025Vaccine Sales Collapse in China as MNCs Struggle with Local Competitio...
  • 7/3/2025AbbVie's Venclexta Approved in China for Second-Line Treatment of del1...
  • 7/3/2025Eli Lilly's Tirzepatide Approved in China for Treatment of Obstructive...
  • 7/3/2025Hengrui Medicine Gains NMPA Approval for Novel Dry Eye Treatment SHR80...
  • 7/3/2025CTTQ's Homegrown rFVIIa Wins NMPA Approval for Bleeding Disorders
  • 7/3/2025Belief BioMed Unveils 4-Year Follow-Up Data for Hemophilia B Gene Ther...
  • 7/3/2025Cloudbreak Pharma Debuts on HKEX, Raising HK$612 Million in IPO
  • Page:4/54 Total number of articles:1606: [First][<<] [2] [3] [4] [5] [6] [>>] [End]
  • Site map | Contact Us | Links
  • © Wicon International Group